Amicus Therapeutics Story Overview

FOLD -- USA Stock  

USD 11.97  0.32  2.60%

Macroaxis does not monitor all media channels or aggregates social signals for Amicus Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Amicus Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Amicus Therapeutics. Additionally see Amicus Therapeutics Hype Analysis, Amicus Therapeutics Correlation and Amicus Therapeutics Performance.
Acquisition by Hung Do of 29803 shares of Amicus Therapeutics subject to Rule 16b-3
Filed transaction by Amicus Therapeutics Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Amicus Therapeutics Inc insider trading alert for grant of common stock by Hung Do, Chief Science Officer, on January 3, 2018. This event was filed by Amicus Therapeutics Inc with SEC on 2018-01-05. Statement of changes in beneficial ownership - SEC Form 4. Hung Do is currently serves as senior vice president - discovery biology of Amicus Therapeutics Inc

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 1.47% . The overall trading delta when the story was published against the current closing price is 21.51% .

Similar stores for Amicus Therapeutics

3 days ago at http://finbulletin.com 
Blunt response to the situation Amicus Therapeutics, Inc. , Patterson-UTI Energy, Inc.
news
FinBulletinFull coverage
Latest alteration Amicus Therapeutics, Inc., , Coty Inc.,news
Nyse Trading News Notable Traders Alert Amicus Therapeutics, Inc., , CNX Resources Corporation, Global Export Lines Amicus Therapeutics, Inc. Traders Attention Alert Talk Traders Full coverage
over a week ago at www.macroaxis.com 
Acquisition by Clark David Michael of 84842 shares of Amicus Therapeutics subject to Rule 16b-3
Macroaxis News
Filed transaction by Amicus Therapeutics Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3
over a week ago at http://globalexportlines.com 
Fascinating Stocks Phillips 66, , Amicus Therapeutics, Inc.,
news
Global Export Lines Stock inside Analysts Limelight Amicus Therapeutics, Inc. Nasdaq Click Sectoral Asset Management INC Has Lifted Amicus Therapeutics Position MoneyMakingArticlesFull coverage
over two weeks ago at http://www.nysetradingnews.com 
Stupefying Stocks Amicus Therapeutics, Inc., , Newmont Mining Corporation,
news
Nyse Trading News Full coverage
over two weeks ago at http://xnewspress.com 
Amicus Therapeutics, Inc. Position Raised by Natixis
news
XNewsPressFull coverage
over three weeks ago at http://finbulletin.com 
Rising up to the challenge Burlington Stores, Inc. , Amicus Therapeutics, Inc.
news
FinBulletinFull coverage
over three weeks ago at http://www.nysetradingnews.com 
It may surprise you Amicus Therapeutics, Inc., , Halcon Resources Corporation,
news
Nyse Trading News Full coverage
over a month ago at www.macroaxis.com 
Conversion by Kramlich C Richard of 1643472 shares of Amicus Therapeutics
Macroaxis News
Filed transaction by Amicus Therapeutics Inc executive. Derivative codes conversion of derivative security
over a month ago at www.macroaxis.com 
Purchase by Topper James N of 500 shares of Amicus Therapeutics
Macroaxis News
Filed transaction by Amicus Therapeutics Inc director. General open market or private purchase of non-derivative or derivative security
over a month ago at http://seekingalpha.com 
Amicus Therapeutics announces regulatory and clinical updates for AT-GAA in pompe disease
seekingalpha News
Seeking AlphaFull coverage
over two months ago at http://globalexportlines.com 
REF Amicus Therapeutics, Inc.,
news
Global Export Lines Birchview Capital LP Holding in Amicus Therapeutics Has Lifted by 360000 as Stock Rose Duke Energy ... D MinuteAmicus Therapeutics, Inc. EPS Estimated At -0.33 Timessquare Capital Management Increased Its Carlisle ... Flecha 123 Full coverage
over three months ago at http://www.prnewswire.com 
Fabrys Disease Pipeline Analysis 2018 Major Players are Actelion Pharmaceuticals, Sanofi, Amicus Therapeutics ...
prnewswire News
PR Newswire Full coverage

EBITDA

EBITDA Comparative Analysis

  EBITDA 
      Amicus Therapeutics Comparables 
Amicus Therapeutics is currently under evaluation in ebitda category among related companies. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Peers

Amicus Therapeutics Related Equities

EARS  12.94 %   
0%
100.0%
DRNA  12.64 %   
0%
97.0%
DVAX  4.61 %   
0%
35.0%
CO  3.77 %   
0%
29.0%
DMPI  3.06 %   
0%
23.0%
NK  1.87 %   
0%
14.0%
DNLI  1.34 %   
0%
10.0%
ECYT  0.41 %   
0%
3.0%
EQ  0.14 %   
1.0%
0%
DOVA  1.73 %   
13.0%
0%
Additionally see Amicus Therapeutics Hype Analysis, Amicus Therapeutics Correlation and Amicus Therapeutics Performance. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Search macroaxis.com